Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 1063

1.

Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial.

Chataway J, De Angelis F, Connick P, Parker RA, Plantone D, Doshi A, John N, Stutters J, MacManus D, Prados Carrasco F, Barkhof F, Ourselin S, Braisher M, Ross M, Cranswick G, Pavitt SH, Giovannoni G, Gandini Wheeler-Kingshott CA, Hawkins C, Sharrack B, Bastow R, Weir CJ, Stallard N, Chandran S; MS-SMART Investigators.

Lancet Neurol. 2020 Jan 22. pii: S1474-4422(19)30485-5. doi: 10.1016/S1474-4422(19)30485-5. [Epub ahead of print]

PMID:
31981516
2.

Ongoing microstructural changes in the cervical cord underpin disability progression in early primary progressive multiple sclerosis.

Cortese R, Tur C, Prados F, Schneider T, Kanber B, Moccia M, Wheeler-Kingshott CAG, Thompson AJ, Barkhof F, Ciccarelli O.

Mult Scler. 2020 Jan 21:1352458519900971. doi: 10.1177/1352458519900971. [Epub ahead of print]

PMID:
31961242
3.

Selection of memory clinic patients for CSF biomarker assessment can be restricted to a quarter of cases by using computerized decision support, without compromising diagnostic accuracy.

Rhodius-Meester HFM, van Maurik IS, Koikkalainen J, Tolonen A, Frederiksen KS, Hasselbalch SG, Soininen H, Herukka SK, Remes AM, Teunissen CE, Barkhof F, Pijnenburg YAL, Scheltens P, Lötjönen J, van der Flier WM.

PLoS One. 2020 Jan 15;15(1):e0226784. doi: 10.1371/journal.pone.0226784. eCollection 2020.

4.

Brain miliary enhancement.

Bot JCJ, Mazzai L, Hagenbeek RE, Ingala S, van Oosten B, Sanchez-Aliaga E, Barkhof F.

Neuroradiology. 2020 Jan 10. doi: 10.1007/s00234-019-02335-5. [Epub ahead of print] Review.

PMID:
31925469
5.

Methylphenidate and galantamine in patients with vascular cognitive impairment-the proof-of-principle study STREAM-VCI.

Leijenaar JF, Groeneveld GJ, Klaassen ES, Leeuwis AE, Scheltens P, Weinstein HC, van Gerven JMA, Barkhof F, van der Flier WM, Prins ND.

Alzheimers Res Ther. 2020 Jan 7;12(1):10. doi: 10.1186/s13195-019-0567-z.

6.

Generalised boundary shift integral for longitudinal assessment of spinal cord atrophy.

Prados F, Moccia M, Johnson A, Yiannakas M, Grussu F, Cardoso MJ, Ciccarelli O, Ourselin S, Barkhof F, Wheeler-Kingshott C.

Neuroimage. 2019 Dec 24;209:116489. doi: 10.1016/j.neuroimage.2019.116489. [Epub ahead of print]

7.

Hippocampal profiling: Localized magnetic resonance imaging volumetry and T2 relaxometry for hippocampal sclerosis.

Vos SB, Winston GP, Goodkin O, Pemberton HG, Barkhof F, Prados F, Galovic M, Koepp M, Ourselin S, Cardoso MJ, Duncan JS.

Epilepsia. 2019 Dec 24. doi: 10.1111/epi.16416. [Epub ahead of print]

PMID:
31872873
8.

PET and CSF amyloid-β status are differently predicted by patient features: information from discordant cases.

Reimand J, de Wilde A, Teunissen CE, Zwan M, Windhorst AD, Boellaard R, Barkhof F, van der Flier WM, Scheltens P, van Berckel BNM, Ossenkoppele R, Bouwman F.

Alzheimers Res Ther. 2019 Dec 7;11(1):100. doi: 10.1186/s13195-019-0561-5.

9.

Why Is Amyloid-β PET Requested After Performing Cerebrospinal Fluid Biomarkers?

Reimand J, Groot C, Teunissen CE, Windhorst AD, Boellaard R, Barkhof F, Nazarenko S, van der Flier WM, van Berckel BNM, Scheltens P, Ossenkoppele R, Bouwman F.

J Alzheimers Dis. 2019 Nov 25. doi: 10.3233/JAD-190836. [Epub ahead of print]

PMID:
31796674
10.

Differences in topological progression profile among neurodegenerative diseases from imaging data.

Garbarino S, Lorenzi M, Oxtoby NP, Vinke EJ, Marinescu RV, Eshaghi A, Ikram MA, Niessen WJ, Ciccarelli O, Barkhof F, Schott JM, Vernooij MW, Alexander DC; Alzheimer’s Disease Neuroimaging Initiative.

Elife. 2019 Dec 13;8. pii: e49298. doi: 10.7554/eLife.49298.

11.

Comorbid amyloid-β pathology affects clinical and imaging features in VCD.

Leijenaar JF, Groot C, Sudre CH, Bergeron D, Leeuwis AE, Cardoso MJ, Carrasco FP, Laforce R Jr, Barkhof F, van der Flier WM, Scheltens P, Prins ND, Ossenkoppele R.

Alzheimers Dement. 2019 Nov 27. pii: S1552-5260(19)35350-6. doi: 10.1016/j.jalz.2019.08.190. [Epub ahead of print]

12.

White matter hyperintensities mediate gray matter volume and processing speed relationship in cognitively unimpaired participants.

Brugulat-Serrat A, Salvadó G, Operto G, Cacciaglia R, Sudre CH, Grau-Rivera O, Suárez-Calvet M, Falcon C, Sánchez-Benavides G, Gramunt N, Minguillon C, Fauria K, Barkhof F, Molinuevo JL, Gispert JD; ALFA Study.

Hum Brain Mapp. 2019 Nov 28. doi: 10.1002/hbm.24877. [Epub ahead of print]

PMID:
31778002
13.

Prion disease diagnosis using subject-specific imaging biomarkers within a multi-kernel Gaussian process.

Canas LS, Sudre CH, De Vita E, Nihat A, Mok TH, Slattery CF, Paterson RW, Foulkes AJM, Hyare H, Cardoso MJ, Thornton J, Schott JM, Barkhof F, Collinge J, Ourselin S, Mead S, Modat M.

Neuroimage Clin. 2019;24:102051. doi: 10.1016/j.nicl.2019.102051. Epub 2019 Oct 25.

14.

Comparing lesion segmentation methods in multiple sclerosis: Input from one manually delineated subject is sufficient for accurate lesion segmentation.

Weeda MM, Brouwer I, de Vos ML, de Vries MS, Barkhof F, Pouwels PJW, Vrenken H.

Neuroimage Clin. 2019;24:102074. doi: 10.1016/j.nicl.2019.102074. Epub 2019 Nov 5.

15.

SVM recursive feature elimination analyses of structural brain MRI predicts near-term relapses in patients with clinically isolated syndromes suggestive of multiple sclerosis.

Wottschel V, Chard DT, Enzinger C, Filippi M, Frederiksen JL, Gasperini C, Giorgio A, Rocca MA, Rovira A, De Stefano N, Tintoré M, Alexander DC, Barkhof F, Ciccarelli O; MAGNIMS study group and the EuroPOND consortium.

Neuroimage Clin. 2019;24:102011. doi: 10.1016/j.nicl.2019.102011. Epub 2019 Oct 22.

16.

Performance of five automated white matter hyperintensity segmentation methods in a multicenter dataset.

Heinen R, Steenwijk MD, Barkhof F, Biesbroek JM, van der Flier WM, Kuijf HJ, Prins ND, Vrenken H, Biessels GJ, de Bresser J; TRACE-VCI study group.

Sci Rep. 2019 Nov 14;9(1):16742. doi: 10.1038/s41598-019-52966-0.

17.

The P2X7 receptor tracer [11C]SMW139 as an in vivo marker of neuroinflammation in multiple sclerosis: a first-in man study.

Hagens MHJ, Golla SSV, Janssen B, Vugts DJ, Beaino W, Windhorst AD, O'Brien-Brown J, Kassiou M, Schuit RC, Schwarte LA, de Vries HE, Killestein J, Barkhof F, van Berckel BNM, Lammertsma AA.

Eur J Nucl Med Mol Imaging. 2020 Feb;47(2):379-389. doi: 10.1007/s00259-019-04550-x. Epub 2019 Nov 8.

PMID:
31705174
18.

Global Burden of Small Vessel Disease-Related Brain Changes on MRI Predicts Cognitive and Functional Decline.

Jokinen H, Koikkalainen J, Laakso HM, Melkas S, Nieminen T, Brander A, Korvenoja A, Rueckert D, Barkhof F, Scheltens P, Schmidt R, Fazekas F, Madureira S, Verdelho A, Wallin A, Wahlund LO, Waldemar G, Chabriat H, Hennerici M, O'Brien J, Inzitari D, Lötjönen J, Pantoni L, Erkinjuntti T.

Stroke. 2020 Jan;51(1):170-178. doi: 10.1161/STROKEAHA.119.026170. Epub 2019 Nov 8.

19.

A 30-Year Clinical and Magnetic Resonance Imaging Observational Study of Multiple Sclerosis and Clinically Isolated Syndromes.

Chung KK, Altmann D, Barkhof F, Miszkiel K, Brex PA, O'Riordan J, Ebner M, Prados F, Cardoso MJ, Vercauteren T, Ourselin S, Thompson A, Ciccarelli O, Chard DT.

Ann Neurol. 2020 Jan;87(1):63-74. doi: 10.1002/ana.25637. Epub 2019 Nov 22.

PMID:
31693200
20.

Facing privacy in neuroimaging: removing facial features degrades performance of image analysis methods.

de Sitter A, Visser M, Brouwer I, Cover KS, van Schijndel RA, Eijgelaar RS, Müller DMJ, Ropele S, Kappos L, Rovira Á, Filippi M, Enzinger C, Frederiksen J, Ciccarelli O, Guttmann CRG, Wattjes MP, Witte MG, de Witt Hamer PC, Barkhof F, Vrenken H; MAGNIMS Study Group and Alzheimer’s Disease Neuroimaging Initiative.

Eur Radiol. 2020 Feb;30(2):1062-1074. doi: 10.1007/s00330-019-06459-3. Epub 2019 Nov 5.

PMID:
31691120
21.

Harmonization of neuroimaging biomarkers for neurodegenerative diseases: A survey in the imaging community of perceived barriers and suggested actions.

Jovicich J, Barkhof F, Babiloni C, Herholz K, Mulert C, van Berckel BNM, Frisoni GB; SRA-NED JPND Working Group.

Alzheimers Dement (Amst). 2019 Jan 10;11:69-73. doi: 10.1016/j.dadm.2018.11.005. eCollection 2019 Dec.

22.

Exploring effects of Souvenaid on cerebral glucose metabolism in Alzheimer's disease.

Scheltens NME, Briels CT, Yaqub M, Barkhof F, Boellaard R, van der Flier WM, Schwarte LA, Teunissen CE, Attali A, Broersen LM, van Berckel BNM, Scheltens P.

Alzheimers Dement (N Y). 2019 Sep 27;5:492-500. doi: 10.1016/j.trci.2019.08.002. eCollection 2019.

23.

Clinically relevant cranio-caudal patterns of cervical cord atrophy evolution in MS.

Rocca MA, Valsasina P, Meani A, Gobbi C, Zecca C, Rovira À, Montalban X, Kearney H, Ciccarelli O, Matthews L, Palace J, Gallo A, Bisecco A, Gass A, Eisele P, Lukas C, Bellenberg B, Barkhof F, Vrenken H, Preziosa P, Comi G, Filippi M; MAGNIMS Study Group.

Neurology. 2019 Nov 12;93(20):e1852-e1866. doi: 10.1212/WNL.0000000000008466. Epub 2019 Oct 14.

PMID:
31611336
24.

Applying the ATN scheme in a memory clinic population: The ABIDE project.

Altomare D, de Wilde A, Ossenkoppele R, Pelkmans W, Bouwman F, Groot C, van Maurik I, Zwan M, Yaqub M, Barkhof F, van Berckel BN, Teunissen CE, Frisoni GB, Scheltens P, van der Flier WM.

Neurology. 2019 Oct 22;93(17):e1635-e1646. doi: 10.1212/WNL.0000000000008361. Epub 2019 Oct 9.

PMID:
31597710
25.

Randomized trial of daily high-dose vitamin D3 in patients with RRMS receiving subcutaneous interferon β-1a.

Hupperts R, Smolders J, Vieth R, Holmøy T, Marhardt K, Schluep M, Killestein J, Barkhof F, Beelke M, Grimaldi LME; SOLAR Study Group.

Neurology. 2019 Nov 12;93(20):e1906-e1916. doi: 10.1212/WNL.0000000000008445. Epub 2019 Oct 8.

PMID:
31594857
26.

Assessment of the appropriate use criteria for amyloid PET in an unselected memory clinic cohort: The ABIDE project.

de Wilde A, Ossenkoppele R, Pelkmans W, Bouwman F, Groot C, van Maurik I, Zwan M, Yaqub M, Barkhof F, Lammertsma AA, Biessels GJ, Scheltens P, van Berckel BN, van der Flier WM.

Alzheimers Dement. 2019 Nov;15(11):1458-1467. doi: 10.1016/j.jalz.2019.07.003. Epub 2019 Oct 6.

27.

Early adaptive immune activation detected in monozygotic twins with prodromal multiple sclerosis.

Beltrán E, Gerdes LA, Hansen J, Flierl-Hecht A, Krebs S, Blum H, Ertl-Wagner B, Barkhof F, Kümpfel T, Hohlfeld R, Dornmair K.

J Clin Invest. 2019 Nov 1;129(11):4758-4768. doi: 10.1172/JCI128475.

28.

Voxelwise statistical methods to localize practice variation in brain tumor surgery.

Eijgelaar R, De Witt Hamer PC, Peeters CFW, Barkhof F, van Herk M, Witte MG.

PLoS One. 2019 Sep 27;14(9):e0222939. doi: 10.1371/journal.pone.0222939. eCollection 2019.

29.

Improved detection of diffuse glioma infiltration with imaging combinations: a diagnostic accuracy study.

Verburg N, Koopman T, Yaqub MM, Hoekstra OS, Lammertsma AA, Barkhof F, Pouwels PJW, Reijneveld JC, Heimans JJ, Rozemuller AJM, Bruynzeel AME, Lagerwaard F, Vandertop WP, Boellaard R, Wesseling P, de Witt Hamer PC.

Neuro Oncol. 2019 Sep 24. pii: noz180. doi: 10.1093/neuonc/noz180. [Epub ahead of print]

PMID:
31550353
30.

Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study.

van Maurik IS, Vos SJ, Bos I, Bouwman FH, Teunissen CE, Scheltens P, Barkhof F, Frolich L, Kornhuber J, Wiltfang J, Maier W, Peters O, Rüther E, Nobili F, Frisoni GB, Spiru L, Freund-Levi Y, Wallin AK, Hampel H, Soininen H, Tsolaki M, Verhey F, Kłoszewska I, Mecocci P, Vellas B, Lovestone S, Galluzzi S, Herukka SK, Santana I, Baldeiras I, de Mendonça A, Silva D, Chetelat G, Egret S, Palmqvist S, Hansson O, Visser PJ, Berkhof J, van der Flier WM; Alzheimer's Disease Neuroimaging Initiative.

Lancet Neurol. 2019 Nov;18(11):1034-1044. doi: 10.1016/S1474-4422(19)30283-2. Epub 2019 Sep 13.

PMID:
31526625
31.

Cerebral amyloid burden is associated with white matter hyperintensity location in specific posterior white matter regions.

Weaver NA, Doeven T, Barkhof F, Biesbroek JM, Groeneveld ON, Kuijf HJ, Prins ND, Scheltens P, Teunissen CE, van der Flier WM, Biessels GJ; TRACE-VCI study group.

Neurobiol Aging. 2019 Dec;84:225-234. doi: 10.1016/j.neurobiolaging.2019.08.001. Epub 2019 Aug 9.

32.

Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosis.

Elliott C, Belachew S, Wolinsky JS, Hauser SL, Kappos L, Barkhof F, Bernasconi C, Fecker J, Model F, Wei W, Arnold DL.

Brain. 2019 Sep 1;142(9):2787-2799. doi: 10.1093/brain/awz212.

33.

Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay.

Shi L, Westwood S, Baird AL, Winchester L, Dobricic V, Kilpert F, Hong S, Franke A, Hye A, Ashton NJ, Morgan AR, Bos I, Vos SJB, Buckley NJ, Kate MT, Scheltens P, Vandenberghe R, Gabel S, Meersmans K, Engelborghs S, De Roeck EE, Sleegers K, Frisoni GB, Blin O, Richardson JC, Bordet R, Molinuevo JL, Rami L, Wallin A, Kettunen P, Tsolaki M, Verhey F, Lleó A, Alcolea D, Popp J, Peyratout G, Martinez-Lage P, Tainta M, Johannsen P, Teunissen CE, Freund-Levi Y, Frölich L, Legido-Quigley C, Barkhof F, Blennow K, Zetterberg H, Baker S, Morgan BP, Streffer J, Visser PJ, Bertram L, Lovestone S, Nevado-Holgado AJ.

Alzheimers Dement. 2019 Nov;15(11):1478-1488. doi: 10.1016/j.jalz.2019.06.4951. Epub 2019 Sep 5.

34.

Cortical atrophy accelerates as cognitive decline worsens in multiple sclerosis.

Eijlers AJC, Dekker I, Steenwijk MD, Meijer KA, Hulst HE, Pouwels PJW, Uitdehaag BMJ, Barkhof F, Vrenken H, Schoonheim MM, Geurts JJG.

Neurology. 2019 Oct 1;93(14):e1348-e1359. doi: 10.1212/WNL.0000000000008198. Epub 2019 Sep 4.

PMID:
31484713
35.

Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis.

Barkhof F, Kappos L, Wolinsky JS, Li DKB, Bar-Or A, Hartung HP, Belachew S, Han J, Julian L, Sauter A, Napieralski J, Koendgen H, Hauser SL.

Neurology. 2019 Nov 5;93(19):e1778-e1786. doi: 10.1212/WNL.0000000000008189. Epub 2019 Sep 4.

PMID:
31484710
36.

Validation of mean upper cervical cord area (MUCCA) measurement techniques in multiple sclerosis (MS): High reproducibility and robustness to lesions, but large software and scanner effects.

Weeda MM, Middelkoop SM, Steenwijk MD, Daams M, Amiri H, Brouwer I, Killestein J, Uitdehaag BMJ, Dekker I, Lukas C, Bellenberg B, Barkhof F, Pouwels PJW, Vrenken H.

Neuroimage Clin. 2019;24:101962. doi: 10.1016/j.nicl.2019.101962. Epub 2019 Aug 6.

37.

Associations of brain pathology, cognitive and physical markers with age in cognitively normal individuals aged 60-102 years.

Legdeur N, Tijms BM, Konijnenberg E, den Braber A, Ten Kate M, Sudre CH, Tomassen J, Badissi M, Yaqub M, Barkhof F, van Berckel BN, Boomsma DI, Scheltens P, Holstege H, Maier AB, Visser PJ.

J Gerontol A Biol Sci Med Sci. 2019 Aug 14. pii: glz180. doi: 10.1093/gerona/glz180. [Epub ahead of print]

PMID:
31411322
38.

Association between tumor location and neurocognitive functioning using tumor localization maps.

Habets EJJ, Hendriks EJ, Taphoorn MJB, Douw L, Zwinderman AH, Vandertop WP, Barkhof F, De Witt Hamer PC, Klein M.

J Neurooncol. 2019 Sep;144(3):573-582. doi: 10.1007/s11060-019-03259-z. Epub 2019 Aug 13.

PMID:
31410731
39.

Longitudinal spinal cord atrophy in multiple sclerosis using the generalized boundary shift integral.

Moccia M, Prados F, Filippi M, Rocca MA, Valsasina P, Brownlee WJ, Zecca C, Gallo A, Rovira A, Gass A, Palace J, Lukas C, Vrenken H, Ourselin S, Gandini Wheeler-Kingshott CAM, Ciccarelli O, Barkhof F; MAGNIMS Study Group.

Ann Neurol. 2019 Nov;86(5):704-713. doi: 10.1002/ana.25571. Epub 2019 Aug 22.

PMID:
31385358
40.

Medial temporal lobe atrophy and posterior atrophy scales normative values.

Cotta Ramusino M, Altomare D, Bacchin R, Ingala S, Bnà C, Bonetti M, Costa A, Barkhof F, Nicolosi V, Festari C, Frisoni GB, Boccardi M.

Neuroimage Clin. 2019;24:101936. doi: 10.1016/j.nicl.2019.101936. Epub 2019 Jul 15.

41.

Infratentorial and spinal cord lesions: Cumulative predictors of long-term disability?

Dekker I, Sombekke MH, Balk LJ, Moraal B, Geurts JJ, Barkhof F, Uitdehaag BM, Killestein J, Wattjes MP.

Mult Scler. 2019 Aug 2:1352458519864933. doi: 10.1177/1352458519864933. [Epub ahead of print]

PMID:
31373535
42.

The quantitative neuroradiology initiative framework: application to dementia.

Goodkin O, Pemberton H, Vos SB, Prados F, Sudre CH, Moggridge J, Cardoso MJ, Ourselin S, Bisdas S, White M, Yousry T, Thornton J, Barkhof F.

Br J Radiol. 2019 Sep;92(1101):20190365. doi: 10.1259/bjr.20190365. Epub 2019 Aug 1. Review.

PMID:
31368776
43.

Multi-study validation of data-driven disease progression models to characterize evolution of biomarkers in Alzheimer's disease.

Archetti D, Ingala S, Venkatraghavan V, Wottschel V, Young AL, Bellio M, Bron EE, Klein S, Barkhof F, Alexander DC, Oxtoby NP, Frisoni GB, Redolfi A; Alzheimer's Disease Neuroimaging Initiative; for EuroPOND Consortium.

Neuroimage Clin. 2019;24:101954. doi: 10.1016/j.nicl.2019.101954. Epub 2019 Jul 23.

44.

Early imaging predictors of long-term outcomes in relapse-onset multiple sclerosis.

Brownlee WJ, Altmann DR, Prados F, Miszkiel KA, Eshaghi A, Gandini Wheeler-Kingshott CAM, Barkhof F, Ciccarelli O.

Brain. 2019 Aug 1;142(8):2276-2287. doi: 10.1093/brain/awz156.

PMID:
31342055
45.

Erratum: Author Correction: High-dimensional detection of imaging response to treatment in multiple sclerosis.

Kanber B, Nachev P, Barkhof F, Calvi A, Cardoso J, Cortese R, Prados F, Sudre CH, Tur C, Ourselin S, Ciccarelli O.

NPJ Digit Med. 2019 Jul 16;2:66. doi: 10.1038/s41746-019-0144-7. eCollection 2019.

46.

Single-subject structural cortical networks in clinically isolated syndrome.

Collorone S, Prados F, Hagens MH, Tur C, Kanber B, Sudre CH, Lukas C, Gasperini C, Oreja-Guevara C, Andelova M, Ciccarelli O, Wattjes MP, Ourselin S, Altmann DR, Tijms BM, Barkhof F, Toosy AT; MAGNIMS Study Group.

Mult Scler. 2019 Jul 24:1352458519865739. doi: 10.1177/1352458519865739. [Epub ahead of print]

47.

Improved performance of the 2017 McDonald criteria for diagnosis of multiple sclerosis in children in a real-life cohort.

Hacohen Y, Brownlee W, Mankad K, Chong WK', Thompson A, Lim M, Wassmer E, Hemingway C, Barkhof F, Ciccarelli O.

Mult Scler. 2019 Jul 18:1352458519863781. doi: 10.1177/1352458519863781. [Epub ahead of print]

PMID:
31317829
48.

High-dimensional detection of imaging response to treatment in multiple sclerosis.

Kanber B, Nachev P, Barkhof F, Calvi A, Cardoso J, Cortese R, Prados F, Sudre CH, Tur C, Ourselin S, Ciccarelli O.

NPJ Digit Med. 2019 Jun 10;2:49. doi: 10.1038/s41746-019-0127-8. eCollection 2019. Erratum in: NPJ Digit Med. 2019 Jul 16;2:66.

49.

Patterns of white matter hyperintensities associated with cognition in middle-aged cognitively healthy individuals.

Brugulat-Serrat A, Salvadó G, Sudre CH, Grau-Rivera O, Suárez-Calvet M, Falcon C, Sánchez-Benavides G, Gramunt N, Fauria K, Cardoso MJ, Barkhof F, Molinuevo JL, Gispert JD; ALFA Study.

Brain Imaging Behav. 2019 Jul 5. doi: 10.1007/s11682-019-00151-2. [Epub ahead of print]

PMID:
31278650
50.

Associations between quantitative [18F]flortaucipir tau PET and atrophy across the Alzheimer's disease spectrum.

Timmers T, Ossenkoppele R, Wolters EE, Verfaillie SCJ, Visser D, Golla SSV, Barkhof F, Scheltens P, Boellaard R, van der Flier WM, van Berckel BNM.

Alzheimers Res Ther. 2019 Jul 4;11(1):60. doi: 10.1186/s13195-019-0510-3.

Supplemental Content

Loading ...
Support Center